Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

VHL antibody (AA 1-213)

VHL Reactivity: Human, Mouse WB, IP, IHC (f) Host: Mouse Monoclonal Ig32 unconjugated
Catalog No. ABIN967508
  • Target See all VHL Antibodies
    VHL (Von Hippel-Lindau Tumor Suppressor, E3 Ubiquitin Protein Ligase (VHL))
    Binding Specificity
    • 16
    • 15
    • 9
    • 5
    • 5
    • 3
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    AA 1-213
    Reactivity
    • 60
    • 37
    • 35
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    Human, Mouse
    Host
    • 65
    • 11
    • 2
    Mouse
    Clonality
    • 70
    • 8
    Monoclonal
    Conjugate
    • 40
    • 5
    • 3
    • 3
    • 3
    • 3
    • 3
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    This VHL antibody is un-conjugated
    Application
    • 45
    • 27
    • 26
    • 26
    • 19
    • 17
    • 12
    • 9
    • 6
    • 3
    • 3
    • 2
    • 1
    Western Blotting (WB), Immunoprecipitation (IP), Immunohistochemistry (Formalin-fixed Sections) (IHC (f))
    Brand
    BD Pharmingen™
    Cross-Reactivity
    Mouse (Murine)
    Characteristics
    1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
    2. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
    3. Please refer to us for technical protocols.
    Purification
    The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.
    Immunogen
    Human VHL aa. 1-213 Recombinant Protein
    Clone
    Ig32
    Isotype
    IgG1 kappa
    Top Product
    Discover our top product VHL Primary Antibody
  • Application Notes
    Western Blot:
    Clone Ig32 is not recommended for Western blot application. It has been shown to recognize a non-specific band above VHL protein. However, RNAi studies have demostrated that clone Ig32 recognizes a fainter band below this dominant band. Also, labs have reported using the 786-O renal cell adenocarcinoma cell line (ATCC CRL-1932, VHL null), siRNA or VHL overexpression to show that clone Ig32 recognizes the VHL protein specifically. Therefore, we recommend using clone Ig32 in over-expressing systems or under native (non-denaturing) conditions such as IHC staining or immunoprecipitation (IP) applications.

    Immunohistochemistry:
    The Ig32 antibody is useful for immunohistochemical staining. Following Retrievagen A pretreatment, purified Ig32 antibody should be used at 2.5 µg/ml to 5 µg/ml and titrated for optimal indirect immunohistochemical staining. Tissues can be visualized via a three-step staining procedure in combination with Biotin Goat anti-Mouse Ig secondary antibody and Streptravidin-HRP together with the DAB Substrate Kit. More conveniently, a Anti-Mouse Ig HRP Detection Kit that contains the biotinylated secondary antibody, antibody diluent, streptavidin-HRP and DAB substrate can be used for staining.
    IP:
    The purified Ig32 antibody has been reported to be useful to immunoprecipitate native human VHL. Please note that this application is not routinely tested. Investigators are advised to determine optimal concentrations for individual applications.
    Restrictions
    For Research Use only
  • Format
    Liquid
    Concentration
    0.5 mg/mL
    Buffer
    Aqueous buffered solution containing ≤0.09 % sodium azide.
    Preservative
    Sodium azide
    Precaution of Use
    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Storage
    4 °C
    Storage Comment
    Store undiluted at 4°C.
  • Hsu, Adereth, Kose, Dammai: "Endocytic function of von Hippel-Lindau tumor suppressor protein regulates surface localization of fibroblast growth factor receptor 1 and cell motility." in: The Journal of biological chemistry, Vol. 281, Issue 17, pp. 12069-80, (2006) (PubMed).

    Qi, Gervais, Li, DeCaprio, Challis, Ohh: "Molecular cloning and characterization of the von Hippel-Lindau-like protein." in: Molecular cancer research : MCR, Vol. 2, Issue 1, pp. 43-52, (2004) (PubMed).

    Baba, Hirai, Kawakami, Kishida, Sakai, Kaneko, Yao, Shuin, Kubota, Hosaka, Ohno: "Tumor suppressor protein VHL is induced at high cell density and mediates contact inhibition of cell growth." in: Oncogene, Vol. 20, Issue 22, pp. 2727-36, (2001) (PubMed).

    Iliopoulos, Ohh, Kaelin: "pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 95, Issue 20, pp. 11661-6, (1998) (PubMed).

    Chen, Kishida, Duh, Renbaum, Orcutt, Schmidt, Zbar: "Suppression of growth of renal carcinoma cells by the von Hippel-Lindau tumor suppressor gene." in: Cancer research, Vol. 55, Issue 21, pp. 4804-7, (1995) (PubMed).

    Iliopoulos, Kibel, Gray, Kaelin: "Tumour suppression by the human von Hippel-Lindau gene product." in: Nature medicine, Vol. 1, Issue 8, pp. 822-6, (1995) (PubMed).

    Kibel, Iliopoulos, DeCaprio, Kaelin: "Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C." in: Science (New York, N.Y.), Vol. 269, Issue 5229, pp. 1444-6, (1995) (PubMed).

  • Target
    VHL (Von Hippel-Lindau Tumor Suppressor, E3 Ubiquitin Protein Ligase (VHL))
    Alternative Name
    VHL (VHL Products)
    Synonyms
    HRCA1 antibody, RCA1 antibody, VHL1 antibody, pVHL antibody, BcDNA:RH61560 antibody, CG13221 antibody, DVhl antibody, Dmel\\CG13221 antibody, Dvhl antibody, VHL antibody, d-VHL antibody, d-vhl antibody, dVHL antibody, dmVHL antibody, vhl antibody, rca1 antibody, vhl1 antibody, hrca1 antibody, zgc:158722 antibody, Vhlh antibody, von Hippel-Lindau tumor suppressor antibody, von Hippel-Lindau antibody, von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase antibody, von Hippel-Lindau disease tumor suppressor antibody, VHL antibody, Vhl antibody, vhl antibody, CpipJ_CPIJ009992 antibody
    Background
    The von Hippel-Lindau (VHL) protein is a tumor suppressor that is highly conserved from Drosophila to mammals. VHL protein normally associates with the transcription factor Elongin. Transcription factors typically act in one of three transcriptional stages, initiation, elongation or termination. Elongin functions by increasing the rate of elongation, the rate at which RNA subunits are added to make an RNA transcript longer. Elongin is made up of three subunits, A, B, and C, and each subunit contributes to the function of the whole protein. VHL binds to Elongin B and C subunits, and appears to prevent Elongin A from associating with the B and C subunits, thereby inhibiting the transcriptional activity of Elongin. The ability of VHL to block Elongin function may play a role in normal cell growth regulation. Mutated VHL sequences lose their ability to bind to Elongin subunits B and C, suggesting that the tumor suppression function of VHL may be linked to its ability to bind to Elongin. Likewise, the introduction of wild-type VHL suppresses growth in tumor cell lines lacking normal expression of VHL genes, further supporting a role for VHL in negative growth regulation. The calculated molecular weight of VHL is 24 kDa. However, different migrating species ranging from 21-30 kDa have been observed using antibodies to VHL, and may result from a variety of factors including alternatively spliced VHL mRNAs and protein degradation. This antibody has been reported to recognize both human and mouse VHL.
    Synonyms: von Hippel-Lindau protein, RCA1, HRCA1
    Molecular Weight
    21-30 kDa
    Pathways
    Tube Formation, Signaling Events mediated by VEGFR1 and VEGFR2, Ubiquitin Proteasome Pathway
You are here:
Support